Barclays’s Vaxcyte PCVX Stock Holding History

Barclays’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-50,000	Closed	-$3.42M	–	5192
2024 Q1	$3.42M	Buy	+50,000	New	+$3.46M	﹤0.01%	2117

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Barclays's PCVX Position: Q2 2026 in Review

Barclays increased its Vaxcyte (PCVX) stake by 22% in Q2 2026, buying an estimated $384K and bringing the position to 39,053 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

Barclays first reported a position in PCVX in Q1 2022 and has held it in 18 quarters since. The position peaked at $24M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Barclays held 39,053 shares of Vaxcyte worth $2.27M as of Q2 2026.
Barclays bought 7,065 Vaxcyte shares in Q2 2026, an estimated $384K.
Vaxcyte made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2270 holding.
Barclays first reported a position in Vaxcyte in Q1 2022 and has held it in 18 quarters since.
Barclays's Vaxcyte position peaked at $24M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.